Fig. 3From: Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patientsClinical measures in patients who switched from infliximab to adalimumab (total of 16 patients). Score shown at 0 (time of switch), 6 and 12 months of Adalimumab treatment. a PGA, b Modified DAS, c CMAS and d MMT. n, number of patients with available data; PGA, Physician Global Assessment; DAS, Disease Activity Score; CMAS, Childhood Myositis Assessment Scale; MMT, Manual Muscle TestingBack to article page